Showing 11 - 20 of 302,639
Persistent link: https://www.econbiz.de/10010614307
Persistent link: https://www.econbiz.de/10010614318
Posaconazole (Noxafil) is an oral, second-generation, extended-spectrum triazole whose approved indications include prophylaxis of invasive fungal disease (IFD) in immunocompromised patients. In pivotal head-to-head trials, posaconazole was significantly more effective in preventing IFD than...
Persistent link: https://www.econbiz.de/10010614335
Persistent link: https://www.econbiz.de/10010614396
Background: Antiplatelet therapy plays a central role in the prevention of atherothrombotic events. Both … Sweden for the prevention of atherothrombotic events based on CAPRIE trial data. The focus of this study is on two high …
Persistent link: https://www.econbiz.de/10008462721
Total hip and knee replacements (THR and TKR) are high-risk settings for venous thromboembolism (VTE). This review summarizes the cost effectiveness of VTE prophylaxis regimens for THR and TKR. We searched MEDLINE (January 1997 to October 2009), EMBASE (January 1997 to June 2009) and the UK NHS...
Persistent link: https://www.econbiz.de/10008505440
Background: Generic ciclosporin A modified (CsA) does not have an equivalent pharmacokinetic profile to branded CsA in some transplant populations, potentially leading to negative clinical consequences and increased long-term costs. Objective: To assess direct healthcare costs for de novo renal...
Persistent link: https://www.econbiz.de/10008489682
The evolution of meningococcal vaccines illustrates nicely the incremental technological process that is common to much medical innovation and particularly appropriate to economic analysis. However, the economic evaluation of vaccines is complicated by several features unique to vaccines,...
Persistent link: https://www.econbiz.de/10008467349
cancer (PCa), they have not demonstrated cost effectiveness in the patient populations in which they have been examined …, prevention with 5ARIs is expected to be cost effective in 50-year-old men with elevated PSA. As a man's risk increases, the cost …
Persistent link: https://www.econbiz.de/10008467353
Respiratory syncytial virus (RSV) is the leading cause of infant hospitalization in the US. The economic burden of severe disease is substantial, including hospitalization costs and out-of-pocket expenses. RSV prophylaxis with either RSV immune globulin intravenous (RSV-IGIV) or palivizumab has...
Persistent link: https://www.econbiz.de/10008602828